Adocia SAS, of Lyon, France, received a patent covering BioChaperone PDGF (platelet-derived growth factor) formulations for chronic wound treatment, including diabetic foot ulcer

plc, of Dublin, Ireland, received Patent No...Avaxia Biologics Inc., of Lexington, Mass., received Patent No

BioLineRx Ltd., of Jerusalem, received a patent term adjustment for its patent on the composition of BCM (BL-1040), a device for prevention of cardiac remodeling following acute myocardial infarction

Omeros Corp., of Seattle, received a patent claiming intraocular surgical methods of using PharmacoSurgery product OMS302, currently in Phase III development

Indel Therapeutics Inc., of Vancouver, British Columbia, received a patent, titled "The Diagnosis and Treatment of Infectious Diseases through Indel-differentiated Proteins," covering claims for indel-based targeting in antimicrobial drug discovery

Indel Therapeutics Inc., of Vancouver, British Columbia, received a patent relating to its antimicrobial drug discovery platform technology...Tris Pharma, of Monmouth Junction, N.J., received a patent for its OralXR platform

Mitomics, of Thunder Bay, Ontario, received a patent covering the specific mitochondrial biomarker used in its Prostate Core Mitomic Test and its use in the detection of prostate cancer

Allon Therapeutics Inc., of Vancouver, British Columbia, received a patent covering the use of its drug candidates, including lead candidate davunetide, for treating laser-induced retinal damage

e-Therapeutics plc, of Newcastle upon Tyne, UK, received a patent for a further key process in its drug discovery platform

Arch Biopartners Inc., of Toronto, received a patent covering the method and composition for an invention preventing or inhibiting the growth of biofilm formation on biotic and abiotic surfaces

PolyTherics Ltd., of London, received a patent covering its method of improving the pharmacokinetic properties of proteins and peptides

Convergen Life Sciences, of Austin, Texas, received a patent covering CNVN202, a targeted molecular therapy in clinical testing in lung cancer

Intellect Neurosciences Inc., of New York, received a patent related to its internal Alzheimer's disease monoclonal antibody program

Adventrx Pharmaceuticals Inc., of San Diego, received a patent, titled "Compositions for Delivering Highly Water Soluble Drugs," which covers formulations of vinorelbine bitartrate and provides protection for the company's lead candidate, ANX-530 (vinorelbine injectable emulsion

PhotoBiotics, of London, received a patent relating to its targeted cancer therapy using its PhotoLink technology for coupling light-activated drugs to antibody fragments

MDRNA Inc., of Bothell, Wash., received a patent covering methods for the delivery of a broad array of compounds with pharmacological activity, including siRNAs, using targeting peptides that have preferential binding affinity for lung tissue

Savara Inc., of Austin, Texas, received a patent allowance for its NanoCluster technology

Regulus Therapeutics Inc., of Carlsbad, Calif., received a patent within the Esau patent estate covering methods of inhibiting miR-122, a liver-specific microRNA that has been shown to facilitate replication of hepatitis C virus infection

PrimeraDx Inc., of Mansfield, Mass., received a patent, titled "Methods and systems for dynamic gene expression profiling," which covers a method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction